Growth Opportunities in Sterile Injectable Outsourcing

Growth Opportunities in Sterile Injectable Outsourcing

Biologics Drive the Future Growth Potential of Sterile Injectable Outsourcing

RELEASE DATE
08-Jun-2022
REGION
North America
Research Code: PD27-01-00-00-00
SKU: HC03548-NA-MT_26593
$2,450.00
In stock
SKU
HC03548-NA-MT_26593
$2,450.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Injectables constitute one of the fastest growing segments in the pharmaceuticals space. Many drugs, including biologics, are going off patent in next 3 or 4 years, which will lead to an increase in the demand for generics and biosimilar injectables. The increase in onshoring and nearshoring
of biopharmaceutical products for COVID-19 and next-generation biologics has significantly increased the demand for aseptic fill-and-finish capacity and capabilities to meet the demand from various regions. All these factors have made sterile injectable drug product services outsourcing the most lucrative opportunity for contract development and manufacturing companies (CDMO)s. The sterile injectable outsourcing market is set to expand at a CAGR of 9.4%% from 2021 to 2026.

Accelerated project timeframes have prompted CDMOs to review their approach and consider strategies that support greater agility in fill-and-finish operations. The development and manufacturing of high-potency small molecules, less-soluble drugs, and targeted small molecules have allowed small-molecule CDMOs to showcase their capabilities and expertise to pharmaceutical partners. Similarly, biologic manufacturing requires advanced manufacturing/quality control technologies, equipment and skill sets. Biopharma companies and innovative biotech players are increasingly outsourcing process development and manufacturing to CDMOs that possess excellent technologies and equipment.

In this report, Frost & Sullivan offers:
• Insights through market forecasts
• Analysis by segment: small-molecule FDF and biologic drug product
• Market trends, drivers, and restraints
• CDMOs’ investment and expansion into injectable capacity
• Opportunities that stakeholders can pursue

Author: Surbhi Gupta

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Sterile Injectables Outsourcing

Growth Opportunities Fuel the Growth Pipeline Engine™

Key Takeaways

Scope of Analysis

Forecast Framework—CDMO

Forecast Methodology—Sterile Injectable Outsourcing

Forecast Assumptions

Key Growth Metrics

Growth Drivers

Growth Restraints

Revenue Forecast

Revenue Forecast by Product Type

Revenue Forecast Analysis

Therapeutic Area Overview

Therapeutic Area Overview (continued)

Supply Chain and the Evolving Role of Vendors

Recent Trends Driving Collaborations & Expansions

Recent Trends Driving Collaborations & Expansions (continued)

Capability Overview of Select CDMOs

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe

CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—APAC

Smartification of Injectable Delivery Device

Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities

Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities (continued)

Growth Opportunity 2: Strategic Partnerships that Provide Integrated Injectable Drug Product and Device Service

Growth Opportunity 2: Strategic Partnerships to Provide Integrated Injectable Drug Product and Device Service (continued)

Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics

Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics (continued)

List of Exhibits

Legal Disclaimer

Injectables constitute one of the fastest growing segments in the pharmaceuticals space. Many drugs, including biologics, are going off patent in next 3 or 4 years, which will lead to an increase in the demand for generics and biosimilar injectables. The increase in onshoring and nearshoring of biopharmaceutical products for COVID-19 and next-generation biologics has significantly increased the demand for aseptic fill-and-finish capacity and capabilities to meet the demand from various regions. All these factors have made sterile injectable drug product services outsourcing the most lucrative opportunity for contract development and manufacturing companies (CDMO)s. The sterile injectable outsourcing market is set to expand at a CAGR of 9.4%% from 2021 to 2026. Accelerated project timeframes have prompted CDMOs to review their approach and consider strategies that support greater agility in fill-and-finish operations. The development and manufacturing of high-potency small molecules, less-soluble drugs, and targeted small molecules have allowed small-molecule CDMOs to showcase their capabilities and expertise to pharmaceutical partners. Similarly, biologic manufacturing requires advanced manufacturing/quality control technologies, equipment and skill sets. Biopharma companies and innovative biotech players are increasingly outsourcing process development and manufacturing to CDMOs that possess excellent technologies and equipment. In this report, Frost & Sullivan offers: • Insights through market forecasts • Analysis by segment: small-molecule FDF and biologic drug product • Market trends, drivers, and restraints • CDMOs’ investment and expansion into injectable capacity • Opportunities that stakeholders can pursue Author: Surbhi Gupta
More Information
Author Surbhi Gupta
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PD27-01-00-00-00